<DOC>
	<DOCNO>NCT01385293</DOCNO>
	<brief_summary>The purpose study evaluate effect study drug , BKM120 . The study drug , BKM120 , inhibitor protein call phosphatidyl inositol-3-kinase ( PI3K ) . This protein find normal cell cancer cell , often many cancer cell protein overactive . Inhibiting protein may slow growth prostate cancer test yet men prostate cancer .</brief_summary>
	<brief_title>BKM120 Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description>This open label , single arm phase II study BKM120 men metastatic castration resistant prostate cancer ( CRPC ) progress follow completion docetaxel-based chemotherapy . Prior progression cabazitaxel , provenge , abiraterone , enzalutamide ( MDV3100 ) also permit . Patients must baseline evaluation perform prior first dose study drug must meet inclusion exclusion criterion . Results baseline evaluation , assure inclusion exclusion criterion satisfy , must review Principal Investigator his/her designee prior enrollment patient . In addition , patient must thoroughly inform aspect study , include study visit schedule require evaluation regulatory requirement inform consent . The write informed consent must obtain patient prior protocol-specific screening test . The following criterion apply patient enrol onto study unless otherwise specify .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Age ≥ 18 year Karnofsky performance status ≥ 70 Life expectancy ≥ 12 week determine treat investigator Adequate laboratory parameter Histologically confirm diagnosis adenocarcinoma prostate . Histologic variant prostate cancer , include neuroendocrine feature small cell carcinoma prostate permit Radiographic evidence metastatic disease Evidence disease progression androgen deprivation therapy ( ADT ) A minimum 4 week elapse antiandrogen therapy prior registration ( i.e . flutamide , nilutamide ) 6 week bicalutamide , without evidence antiandrogen withdrawal response . Patients PSA decline recent antiandrogen therapy require 2 week washout period prior registration A minimum 2 week prior abiraterone acetate , sipuleucelT , MDV3100 , orteronel ( TAK700 ) , ketoconazole , experimental anticancer therapy prior registration require . Concomitant treatment enzalutamide permit . At least one prior systemic chemotherapy regimen FDA approve metastatic prostate cancer A minimum 4 week major surgery prior registration Have receive prior treatment PI3K inhibitor Known hypersensitivity BKM120 excipients Untreated brain metastasis Patients hepatitis B C , acute chronic liver disease , recent ( within 12 month administration first dose study drug ) history pancreatitis Patients certain mood disorder judge investigator psychiatrist History treatment inpatient psychiatric set Concurrent severe and/or uncontrolled cardiac condition could compromise participation study Other concurrent severe and/or uncontrolled concomitant medical condition could cause unacceptable safety risk compromise compliance protocol Uncontrolled diabetes mellitus define fast plasma glucose level &gt; 120 . Diarrhea ≥ CTCAE grade 2 Drugs substance know strong inhibitor inducer isoenzyme CYP3A4 avoid systemic therapy association BKM120 alter metabolism . Topical use cream application absorb circulation permit Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Have treat granulocyte colonystimulating growth factor ( e.g. , GCSF , GMCSF ) ≤ 2 week prior start study drug . Erythropoietin darbepoetin therapy , initiate least 2 week prior enrollment , may continue Currently receive treatment medication potential significantly prolong QT interval induce Torsades de Pointes , treatment either discontinue switched different medication prior start study drug Have receive immunosuppressive therapy include corticosteroid ≤ 2 week prior start study drug . Prednisone total daily dose 10 mg orally equivalent permit , initiate least 2 week prior enrollment History solid organ stem cell transplantation Have receive wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug recover side effect therapy prior administration first dose study drug Have undergone major surgery ≤ 4 week prior start study drug recover side effect therapy prior administration first dose study drug Currently take therapeutic dos warfarin sodium coumadinderivative anticoagulant Known diagnosis human immunodeficiency virus ( HIV ) infection History another malignancy within 3 year , except cure basal cell squamous cell carcinoma skin low grade papillary bladder cancer Other inclusion exclusion criterion apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BKM120</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>metastatic castrate-resistant prostate cancer ( mCRPC )</keyword>
</DOC>